When available, the Online Course format is included with the hard copy, eBook, or audio book formats!
Release Date: June 29, 2012
Revised Date: June 26, 2015
Expiration Date: June 25, 2018
Both periodontal disease and osteoporosis are serious public-health concerns in the United States. There is evidence that osteoporosis, and the characteristic loss of bone mass, is associated with periodontal disease and tooth loss. To optimize the oral health care of patients with osteoporosis and at risk for the condition, dentists and other members of the dental team should be aware of the clinical (and possibly pathophysiologic) link between these increasingly common conditions.
This intermediate-level course addresses current concepts regarding links between oral health and osteoporosis, discusses the impact on oral health of pharmacotherapies used in the treatment of osteoporosis, and outlines steps to mitigate the impact on oral health of common drug treatments used to treat osteoporosis. Oral healthcare providers must recognize the oral health implications of common therapeutic options for osteoporosis, especially use of bisphosphonates and antiresorptive medications. In particular, patient exposure to bisphosphonate and antiresorptive drugs has led to increasing reports of osteonecrosis of the jaw. This serious and debilitating condition requires dental practitioners to be alert for signs and symptoms of this syndrome and to take steps to mitigate risk factors. Although the pharmacotherapy used to treat osteoporosis causes concerns for oral health providers, these drugs provide very significant healthcare advantages for the patients, and overall the reduction in osteoporotic fractures alone causes significant savings for the healthcare system. Therefore, care must be taken not to overestimate the oral health ramifications and concerns with these drugs.
AGD Subject Code: 730
Western Schools designates this activity for 2 continuing education credits.
- Describe the etiology and prevalence of osteoporosis.
- Discuss the putative association between osteoporosis and periodontal disease.
- Explain the pharmacological treatment of osteoporosis.
- Describe the oral health implications of medically related jaw necrosis.
- Identify evidence-based guidelines for the management of bisphosphonate-treated patients.
- Describe the importance of screening for osteoporosis.
John F. Kross, DMD, MSc, received his doctor of dental medicine degree from Temple University School of Dentistry in Philadelphia. He completed a fellowship at Temple University Hospital in oral oncology and received a hospital appointment to the Department of Dentistry at the Medical Centers of Delaware (now the Christiana Health Care System). His professional training and experience includes practicing general dentistry in Wilmington, Delaware, and New London, Pennsylvania, as well as instructing students in oral pathology at Delaware Technical Community College. He has been composing monographs, creating manuscripts, and contributing to continuing dental education since 1991. Dr. Kross has received numerous academic awards for his work in oral surgery, fixed partial prosthodontics, periodontics, and endodontics.
- Courses must be completed within one (1) year of the date of purchase or by the expiration date indicated above, whichever date comes first.
- You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
- Through our review processes, Western Schools ensures that the course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
- All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
There are no prerequisites for this course.